Abstract
The optimal perioperative regimens for hepatocellular carcinoma (HCC) remains undefined. The combination of immune checkpoint inhibitor camrelizumab plus VEGFR2 tyrosine kinase inhibitor apatinib have been approved for treating advanced HCC. This study aimed to explore the efficacy and safety of perioperative (neoadjuvant and adjuvant) or postoperative (adjuvant) camrelizumab plus apatinib for resectable HCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
